nodes	percent_of_prediction	percent_of_DWPC	metapath
Acamprosate—Vertigo—Mycophenolate mofetil—systemic scleroderma	0.000634	0.000634	CcSEcCtD
Acamprosate—Syncope—Mycophenolate mofetil—systemic scleroderma	0.000633	0.000633	CcSEcCtD
Acamprosate—Erectile dysfunction—Prednisone—systemic scleroderma	0.000632	0.000632	CcSEcCtD
Acamprosate—Leukopenia—Mycophenolate mofetil—systemic scleroderma	0.000631	0.000631	CcSEcCtD
Acamprosate—Feeling abnormal—Leflunomide—systemic scleroderma	0.00063	0.00063	CcSEcCtD
Acamprosate—Gastrointestinal disorder—Mycophenolic acid—systemic scleroderma	0.00063	0.00063	CcSEcCtD
Acamprosate—Nausea—Mometasone—systemic scleroderma	0.000628	0.000628	CcSEcCtD
Acamprosate—Anorexia—Lisinopril—systemic scleroderma	0.000626	0.000626	CcSEcCtD
Acamprosate—Gastrointestinal pain—Leflunomide—systemic scleroderma	0.000625	0.000625	CcSEcCtD
Acamprosate—Weight increased—Prednisone—systemic scleroderma	0.000625	0.000625	CcSEcCtD
Acamprosate—Pain—Mycophenolic acid—systemic scleroderma	0.000624	0.000624	CcSEcCtD
Acamprosate—Constipation—Mycophenolic acid—systemic scleroderma	0.000624	0.000624	CcSEcCtD
Acamprosate—Palpitations—Mycophenolate mofetil—systemic scleroderma	0.000623	0.000623	CcSEcCtD
Acamprosate—Weight decreased—Prednisone—systemic scleroderma	0.000621	0.000621	CcSEcCtD
Acamprosate—Loss of consciousness—Mycophenolate mofetil—systemic scleroderma	0.00062	0.00062	CcSEcCtD
Acamprosate—Hyperglycaemia—Prednisone—systemic scleroderma	0.000619	0.000619	CcSEcCtD
Acamprosate—Cough—Mycophenolate mofetil—systemic scleroderma	0.000616	0.000616	CcSEcCtD
Acamprosate—Hypotension—Lisinopril—systemic scleroderma	0.000614	0.000614	CcSEcCtD
Acamprosate—Dizziness—Captopril—systemic scleroderma	0.000614	0.000614	CcSEcCtD
Acamprosate—Liver function test abnormal—Methotrexate—systemic scleroderma	0.000613	0.000613	CcSEcCtD
Acamprosate—Convulsion—Mycophenolate mofetil—systemic scleroderma	0.000611	0.000611	CcSEcCtD
Acamprosate—Depression—Prednisone—systemic scleroderma	0.00061	0.00061	CcSEcCtD
Acamprosate—Hypertension—Mycophenolate mofetil—systemic scleroderma	0.000609	0.000609	CcSEcCtD
Acamprosate—Urticaria—Leflunomide—systemic scleroderma	0.000608	0.000608	CcSEcCtD
Acamprosate—Abdominal pain—Leflunomide—systemic scleroderma	0.000605	0.000605	CcSEcCtD
Acamprosate—Body temperature increased—Leflunomide—systemic scleroderma	0.000605	0.000605	CcSEcCtD
Acamprosate—Acute coronary syndrome—Prednisone—systemic scleroderma	0.000603	0.000603	CcSEcCtD
Acamprosate—Feeling abnormal—Mycophenolic acid—systemic scleroderma	0.000601	0.000601	CcSEcCtD
Acamprosate—Chest pain—Mycophenolate mofetil—systemic scleroderma	0.000601	0.000601	CcSEcCtD
Acamprosate—Myalgia—Mycophenolate mofetil—systemic scleroderma	0.000601	0.000601	CcSEcCtD
Acamprosate—Arthralgia—Mycophenolate mofetil—systemic scleroderma	0.000601	0.000601	CcSEcCtD
Acamprosate—Myocardial infarction—Prednisone—systemic scleroderma	0.0006	0.0006	CcSEcCtD
Acamprosate—Breast disorder—Methotrexate—systemic scleroderma	0.0006	0.0006	CcSEcCtD
Acamprosate—Musculoskeletal discomfort—Lisinopril—systemic scleroderma	0.000599	0.000599	CcSEcCtD
Acamprosate—Anxiety—Mycophenolate mofetil—systemic scleroderma	0.000599	0.000599	CcSEcCtD
Acamprosate—Hypersensitivity—Azathioprine—systemic scleroderma	0.000597	0.000597	CcSEcCtD
Acamprosate—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	0.000597	0.000597	CcSEcCtD
Acamprosate—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic scleroderma	0.000596	0.000596	CcSEcCtD
Acamprosate—Insomnia—Lisinopril—systemic scleroderma	0.000594	0.000594	CcSEcCtD
Acamprosate—Discomfort—Mycophenolate mofetil—systemic scleroderma	0.000593	0.000593	CcSEcCtD
Acamprosate—Paraesthesia—Lisinopril—systemic scleroderma	0.00059	0.00059	CcSEcCtD
Acamprosate—Vomiting—Captopril—systemic scleroderma	0.00059	0.00059	CcSEcCtD
Acamprosate—Dry mouth—Mycophenolate mofetil—systemic scleroderma	0.000587	0.000587	CcSEcCtD
Acamprosate—Dyspnoea—Lisinopril—systemic scleroderma	0.000586	0.000586	CcSEcCtD
Acamprosate—Rash—Captopril—systemic scleroderma	0.000585	0.000585	CcSEcCtD
Acamprosate—Dermatitis—Captopril—systemic scleroderma	0.000585	0.000585	CcSEcCtD
Acamprosate—Somnolence—Lisinopril—systemic scleroderma	0.000584	0.000584	CcSEcCtD
Acamprosate—Headache—Captopril—systemic scleroderma	0.000581	0.000581	CcSEcCtD
Acamprosate—Confusional state—Mycophenolate mofetil—systemic scleroderma	0.000581	0.000581	CcSEcCtD
Acamprosate—Dyspepsia—Lisinopril—systemic scleroderma	0.000578	0.000578	CcSEcCtD
Acamprosate—Abdominal pain—Mycophenolic acid—systemic scleroderma	0.000577	0.000577	CcSEcCtD
Acamprosate—Body temperature increased—Mycophenolic acid—systemic scleroderma	0.000577	0.000577	CcSEcCtD
Acamprosate—Anaphylactic shock—Mycophenolate mofetil—systemic scleroderma	0.000576	0.000576	CcSEcCtD
Acamprosate—Asthma—Methotrexate—systemic scleroderma	0.000574	0.000574	CcSEcCtD
Acamprosate—Infection—Mycophenolate mofetil—systemic scleroderma	0.000572	0.000572	CcSEcCtD
Acamprosate—Decreased appetite—Lisinopril—systemic scleroderma	0.000571	0.000571	CcSEcCtD
Acamprosate—Eosinophilia—Methotrexate—systemic scleroderma	0.000568	0.000568	CcSEcCtD
Acamprosate—Gastrointestinal disorder—Lisinopril—systemic scleroderma	0.000567	0.000567	CcSEcCtD
Acamprosate—Shock—Mycophenolate mofetil—systemic scleroderma	0.000566	0.000566	CcSEcCtD
Acamprosate—Thrombocytopenia—Mycophenolate mofetil—systemic scleroderma	0.000564	0.000564	CcSEcCtD
Acamprosate—Hypersensitivity—Leflunomide—systemic scleroderma	0.000563	0.000563	CcSEcCtD
Acamprosate—Pancreatitis—Methotrexate—systemic scleroderma	0.000562	0.000562	CcSEcCtD
Acamprosate—Pain—Lisinopril—systemic scleroderma	0.000562	0.000562	CcSEcCtD
Acamprosate—Constipation—Lisinopril—systemic scleroderma	0.000562	0.000562	CcSEcCtD
Acamprosate—Tachycardia—Mycophenolate mofetil—systemic scleroderma	0.000562	0.000562	CcSEcCtD
Acamprosate—Skin disorder—Mycophenolate mofetil—systemic scleroderma	0.000559	0.000559	CcSEcCtD
Acamprosate—Hyperhidrosis—Mycophenolate mofetil—systemic scleroderma	0.000557	0.000557	CcSEcCtD
Acamprosate—Diarrhoea—Azathioprine—systemic scleroderma	0.000554	0.000554	CcSEcCtD
Acamprosate—Haemoglobin—Prednisone—systemic scleroderma	0.000552	0.000552	CcSEcCtD
Acamprosate—Nausea—Captopril—systemic scleroderma	0.000551	0.000551	CcSEcCtD
Acamprosate—Haemorrhage—Prednisone—systemic scleroderma	0.000549	0.000549	CcSEcCtD
Acamprosate—Anorexia—Mycophenolate mofetil—systemic scleroderma	0.000549	0.000549	CcSEcCtD
Acamprosate—Asthenia—Leflunomide—systemic scleroderma	0.000549	0.000549	CcSEcCtD
Acamprosate—Hallucination—Prednisone—systemic scleroderma	0.000547	0.000547	CcSEcCtD
Acamprosate—Feeling abnormal—Lisinopril—systemic scleroderma	0.000542	0.000542	CcSEcCtD
Acamprosate—Pruritus—Leflunomide—systemic scleroderma	0.000541	0.000541	CcSEcCtD
Acamprosate—Hypotension—Mycophenolate mofetil—systemic scleroderma	0.000538	0.000538	CcSEcCtD
Acamprosate—Gastrointestinal pain—Lisinopril—systemic scleroderma	0.000537	0.000537	CcSEcCtD
Acamprosate—Dizziness—Azathioprine—systemic scleroderma	0.000536	0.000536	CcSEcCtD
Acamprosate—Erectile dysfunction—Methotrexate—systemic scleroderma	0.000528	0.000528	CcSEcCtD
Acamprosate—Musculoskeletal discomfort—Mycophenolate mofetil—systemic scleroderma	0.000525	0.000525	CcSEcCtD
Acamprosate—Photosensitivity reaction—Methotrexate—systemic scleroderma	0.000524	0.000524	CcSEcCtD
Acamprosate—Asthenia—Mycophenolic acid—systemic scleroderma	0.000523	0.000523	CcSEcCtD
Acamprosate—Diarrhoea—Leflunomide—systemic scleroderma	0.000523	0.000523	CcSEcCtD
Acamprosate—Urticaria—Lisinopril—systemic scleroderma	0.000522	0.000522	CcSEcCtD
Acamprosate—Insomnia—Mycophenolate mofetil—systemic scleroderma	0.000521	0.000521	CcSEcCtD
Acamprosate—Abdominal pain—Lisinopril—systemic scleroderma	0.000519	0.000519	CcSEcCtD
Acamprosate—Body temperature increased—Lisinopril—systemic scleroderma	0.000519	0.000519	CcSEcCtD
Acamprosate—Paraesthesia—Mycophenolate mofetil—systemic scleroderma	0.000517	0.000517	CcSEcCtD
Acamprosate—Pruritus—Mycophenolic acid—systemic scleroderma	0.000516	0.000516	CcSEcCtD
Acamprosate—Vomiting—Azathioprine—systemic scleroderma	0.000515	0.000515	CcSEcCtD
Acamprosate—Pneumonia—Methotrexate—systemic scleroderma	0.000514	0.000514	CcSEcCtD
Acamprosate—Dyspnoea—Mycophenolate mofetil—systemic scleroderma	0.000513	0.000513	CcSEcCtD
Acamprosate—Somnolence—Mycophenolate mofetil—systemic scleroderma	0.000512	0.000512	CcSEcCtD
Acamprosate—Rash—Azathioprine—systemic scleroderma	0.000511	0.000511	CcSEcCtD
Acamprosate—Dermatitis—Azathioprine—systemic scleroderma	0.00051	0.00051	CcSEcCtD
Acamprosate—Depression—Methotrexate—systemic scleroderma	0.00051	0.00051	CcSEcCtD
Acamprosate—Headache—Azathioprine—systemic scleroderma	0.000507	0.000507	CcSEcCtD
Acamprosate—Dyspepsia—Mycophenolate mofetil—systemic scleroderma	0.000507	0.000507	CcSEcCtD
Acamprosate—Dizziness—Leflunomide—systemic scleroderma	0.000506	0.000506	CcSEcCtD
Acamprosate—Decreased appetite—Mycophenolate mofetil—systemic scleroderma	0.000501	0.000501	CcSEcCtD
Acamprosate—Diarrhoea—Mycophenolic acid—systemic scleroderma	0.000499	0.000499	CcSEcCtD
Acamprosate—Stomatitis—Methotrexate—systemic scleroderma	0.000498	0.000498	CcSEcCtD
Acamprosate—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	0.000497	0.000497	CcSEcCtD
Acamprosate—Immune system disorder—Prednisone—systemic scleroderma	0.000496	0.000496	CcSEcCtD
Acamprosate—Constipation—Mycophenolate mofetil—systemic scleroderma	0.000492	0.000492	CcSEcCtD
Acamprosate—Pain—Mycophenolate mofetil—systemic scleroderma	0.000492	0.000492	CcSEcCtD
Acamprosate—Sweating—Methotrexate—systemic scleroderma	0.00049	0.00049	CcSEcCtD
Acamprosate—Haematuria—Methotrexate—systemic scleroderma	0.000488	0.000488	CcSEcCtD
Acamprosate—Vomiting—Leflunomide—systemic scleroderma	0.000486	0.000486	CcSEcCtD
Acamprosate—Alopecia—Prednisone—systemic scleroderma	0.000485	0.000485	CcSEcCtD
Acamprosate—Hypersensitivity—Lisinopril—systemic scleroderma	0.000484	0.000484	CcSEcCtD
Acamprosate—Dizziness—Mycophenolic acid—systemic scleroderma	0.000482	0.000482	CcSEcCtD
Acamprosate—Epistaxis—Methotrexate—systemic scleroderma	0.000482	0.000482	CcSEcCtD
Acamprosate—Rash—Leflunomide—systemic scleroderma	0.000482	0.000482	CcSEcCtD
Acamprosate—Dermatitis—Leflunomide—systemic scleroderma	0.000482	0.000482	CcSEcCtD
Acamprosate—Mental disorder—Prednisone—systemic scleroderma	0.000481	0.000481	CcSEcCtD
Acamprosate—Nausea—Azathioprine—systemic scleroderma	0.000481	0.000481	CcSEcCtD
Acamprosate—Headache—Leflunomide—systemic scleroderma	0.000479	0.000479	CcSEcCtD
Acamprosate—Malnutrition—Prednisone—systemic scleroderma	0.000478	0.000478	CcSEcCtD
Acamprosate—Feeling abnormal—Mycophenolate mofetil—systemic scleroderma	0.000474	0.000474	CcSEcCtD
Acamprosate—Asthenia—Lisinopril—systemic scleroderma	0.000471	0.000471	CcSEcCtD
Acamprosate—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	0.000471	0.000471	CcSEcCtD
Acamprosate—Pruritus—Lisinopril—systemic scleroderma	0.000465	0.000465	CcSEcCtD
Acamprosate—Vomiting—Mycophenolic acid—systemic scleroderma	0.000464	0.000464	CcSEcCtD
Acamprosate—Haemoglobin—Methotrexate—systemic scleroderma	0.000461	0.000461	CcSEcCtD
Acamprosate—Rash—Mycophenolic acid—systemic scleroderma	0.00046	0.00046	CcSEcCtD
Acamprosate—Dermatitis—Mycophenolic acid—systemic scleroderma	0.00046	0.00046	CcSEcCtD
Acamprosate—Hepatitis—Methotrexate—systemic scleroderma	0.000459	0.000459	CcSEcCtD
Acamprosate—Haemorrhage—Methotrexate—systemic scleroderma	0.000459	0.000459	CcSEcCtD
Acamprosate—Urticaria—Mycophenolate mofetil—systemic scleroderma	0.000457	0.000457	CcSEcCtD
Acamprosate—Headache—Mycophenolic acid—systemic scleroderma	0.000457	0.000457	CcSEcCtD
Acamprosate—Pharyngitis—Methotrexate—systemic scleroderma	0.000456	0.000456	CcSEcCtD
Acamprosate—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	0.000455	0.000455	CcSEcCtD
Acamprosate—Body temperature increased—Mycophenolate mofetil—systemic scleroderma	0.000455	0.000455	CcSEcCtD
Acamprosate—Nausea—Leflunomide—systemic scleroderma	0.000454	0.000454	CcSEcCtD
Acamprosate—Diarrhoea—Lisinopril—systemic scleroderma	0.00045	0.00045	CcSEcCtD
Acamprosate—Ill-defined disorder—Prednisone—systemic scleroderma	0.000444	0.000444	CcSEcCtD
Acamprosate—Visual impairment—Methotrexate—systemic scleroderma	0.000442	0.000442	CcSEcCtD
Acamprosate—Anaemia—Prednisone—systemic scleroderma	0.000442	0.000442	CcSEcCtD
Acamprosate—Agitation—Prednisone—systemic scleroderma	0.000439	0.000439	CcSEcCtD
Acamprosate—Angioedema—Prednisone—systemic scleroderma	0.000437	0.000437	CcSEcCtD
Acamprosate—Dizziness—Lisinopril—systemic scleroderma	0.000435	0.000435	CcSEcCtD
Acamprosate—Nausea—Mycophenolic acid—systemic scleroderma	0.000433	0.000433	CcSEcCtD
Acamprosate—Malaise—Prednisone—systemic scleroderma	0.000431	0.000431	CcSEcCtD
Acamprosate—Vertigo—Prednisone—systemic scleroderma	0.00043	0.00043	CcSEcCtD
Acamprosate—Syncope—Prednisone—systemic scleroderma	0.000429	0.000429	CcSEcCtD
Acamprosate—Tinnitus—Methotrexate—systemic scleroderma	0.000428	0.000428	CcSEcCtD
Acamprosate—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	0.000424	0.000424	CcSEcCtD
Acamprosate—Loss of consciousness—Prednisone—systemic scleroderma	0.00042	0.00042	CcSEcCtD
Acamprosate—Vomiting—Lisinopril—systemic scleroderma	0.000418	0.000418	CcSEcCtD
Acamprosate—Immune system disorder—Methotrexate—systemic scleroderma	0.000415	0.000415	CcSEcCtD
Acamprosate—Rash—Lisinopril—systemic scleroderma	0.000414	0.000414	CcSEcCtD
Acamprosate—Convulsion—Prednisone—systemic scleroderma	0.000414	0.000414	CcSEcCtD
Acamprosate—Dermatitis—Lisinopril—systemic scleroderma	0.000414	0.000414	CcSEcCtD
Acamprosate—Asthenia—Mycophenolate mofetil—systemic scleroderma	0.000413	0.000413	CcSEcCtD
Acamprosate—Hypertension—Prednisone—systemic scleroderma	0.000413	0.000413	CcSEcCtD
Acamprosate—Chills—Methotrexate—systemic scleroderma	0.000412	0.000412	CcSEcCtD
Acamprosate—Headache—Lisinopril—systemic scleroderma	0.000412	0.000412	CcSEcCtD
Acamprosate—Pruritus—Mycophenolate mofetil—systemic scleroderma	0.000407	0.000407	CcSEcCtD
Acamprosate—Arthralgia—Prednisone—systemic scleroderma	0.000407	0.000407	CcSEcCtD
Acamprosate—Myalgia—Prednisone—systemic scleroderma	0.000407	0.000407	CcSEcCtD
Acamprosate—Anxiety—Prednisone—systemic scleroderma	0.000406	0.000406	CcSEcCtD
Acamprosate—Alopecia—Methotrexate—systemic scleroderma	0.000406	0.000406	CcSEcCtD
Acamprosate—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic scleroderma	0.000404	0.000404	CcSEcCtD
Acamprosate—Discomfort—Prednisone—systemic scleroderma	0.000402	0.000402	CcSEcCtD
Acamprosate—Mental disorder—Methotrexate—systemic scleroderma	0.000402	0.000402	CcSEcCtD
Acamprosate—Malnutrition—Methotrexate—systemic scleroderma	0.0004	0.0004	CcSEcCtD
Acamprosate—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	0.000394	0.000394	CcSEcCtD
Acamprosate—Dysgeusia—Methotrexate—systemic scleroderma	0.000391	0.000391	CcSEcCtD
Acamprosate—Nausea—Lisinopril—systemic scleroderma	0.00039	0.00039	CcSEcCtD
Acamprosate—Anaphylactic shock—Prednisone—systemic scleroderma	0.00039	0.00039	CcSEcCtD
Acamprosate—Infection—Prednisone—systemic scleroderma	0.000388	0.000388	CcSEcCtD
Acamprosate—Back pain—Methotrexate—systemic scleroderma	0.000387	0.000387	CcSEcCtD
Acamprosate—Shock—Prednisone—systemic scleroderma	0.000384	0.000384	CcSEcCtD
Acamprosate—Tachycardia—Prednisone—systemic scleroderma	0.000381	0.000381	CcSEcCtD
Acamprosate—Dizziness—Mycophenolate mofetil—systemic scleroderma	0.000381	0.000381	CcSEcCtD
Acamprosate—Skin disorder—Prednisone—systemic scleroderma	0.000379	0.000379	CcSEcCtD
Acamprosate—Hyperhidrosis—Prednisone—systemic scleroderma	0.000377	0.000377	CcSEcCtD
Acamprosate—Anorexia—Prednisone—systemic scleroderma	0.000372	0.000372	CcSEcCtD
Acamprosate—Ill-defined disorder—Methotrexate—systemic scleroderma	0.000371	0.000371	CcSEcCtD
Acamprosate—Anaemia—Methotrexate—systemic scleroderma	0.000369	0.000369	CcSEcCtD
Acamprosate—Vomiting—Mycophenolate mofetil—systemic scleroderma	0.000366	0.000366	CcSEcCtD
Acamprosate—Rash—Mycophenolate mofetil—systemic scleroderma	0.000363	0.000363	CcSEcCtD
Acamprosate—Dermatitis—Mycophenolate mofetil—systemic scleroderma	0.000363	0.000363	CcSEcCtD
Acamprosate—Headache—Mycophenolate mofetil—systemic scleroderma	0.000361	0.000361	CcSEcCtD
Acamprosate—Malaise—Methotrexate—systemic scleroderma	0.00036	0.00036	CcSEcCtD
Acamprosate—Vertigo—Methotrexate—systemic scleroderma	0.000359	0.000359	CcSEcCtD
Acamprosate—Leukopenia—Methotrexate—systemic scleroderma	0.000358	0.000358	CcSEcCtD
Acamprosate—Musculoskeletal discomfort—Prednisone—systemic scleroderma	0.000356	0.000356	CcSEcCtD
Acamprosate—Insomnia—Prednisone—systemic scleroderma	0.000353	0.000353	CcSEcCtD
Acamprosate—Paraesthesia—Prednisone—systemic scleroderma	0.00035	0.00035	CcSEcCtD
Acamprosate—Cough—Methotrexate—systemic scleroderma	0.000349	0.000349	CcSEcCtD
Acamprosate—Convulsion—Methotrexate—systemic scleroderma	0.000346	0.000346	CcSEcCtD
Acamprosate—Dyspepsia—Prednisone—systemic scleroderma	0.000344	0.000344	CcSEcCtD
Acamprosate—Nausea—Mycophenolate mofetil—systemic scleroderma	0.000342	0.000342	CcSEcCtD
Acamprosate—Chest pain—Methotrexate—systemic scleroderma	0.00034	0.00034	CcSEcCtD
Acamprosate—Arthralgia—Methotrexate—systemic scleroderma	0.00034	0.00034	CcSEcCtD
Acamprosate—Myalgia—Methotrexate—systemic scleroderma	0.00034	0.00034	CcSEcCtD
Acamprosate—Decreased appetite—Prednisone—systemic scleroderma	0.000339	0.000339	CcSEcCtD
Acamprosate—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic scleroderma	0.000338	0.000338	CcSEcCtD
Acamprosate—Discomfort—Methotrexate—systemic scleroderma	0.000336	0.000336	CcSEcCtD
Acamprosate—Constipation—Prednisone—systemic scleroderma	0.000334	0.000334	CcSEcCtD
Acamprosate—Confusional state—Methotrexate—systemic scleroderma	0.000329	0.000329	CcSEcCtD
Acamprosate—Anaphylactic shock—Methotrexate—systemic scleroderma	0.000326	0.000326	CcSEcCtD
Acamprosate—Infection—Methotrexate—systemic scleroderma	0.000324	0.000324	CcSEcCtD
Acamprosate—Feeling abnormal—Prednisone—systemic scleroderma	0.000322	0.000322	CcSEcCtD
Acamprosate—Thrombocytopenia—Methotrexate—systemic scleroderma	0.000319	0.000319	CcSEcCtD
Acamprosate—Gastrointestinal pain—Prednisone—systemic scleroderma	0.000319	0.000319	CcSEcCtD
Acamprosate—Skin disorder—Methotrexate—systemic scleroderma	0.000317	0.000317	CcSEcCtD
Acamprosate—Hyperhidrosis—Methotrexate—systemic scleroderma	0.000315	0.000315	CcSEcCtD
Acamprosate—Anorexia—Methotrexate—systemic scleroderma	0.000311	0.000311	CcSEcCtD
Acamprosate—Urticaria—Prednisone—systemic scleroderma	0.00031	0.00031	CcSEcCtD
Acamprosate—Body temperature increased—Prednisone—systemic scleroderma	0.000309	0.000309	CcSEcCtD
Acamprosate—Abdominal pain—Prednisone—systemic scleroderma	0.000309	0.000309	CcSEcCtD
Acamprosate—Hypotension—Methotrexate—systemic scleroderma	0.000305	0.000305	CcSEcCtD
Acamprosate—Musculoskeletal discomfort—Methotrexate—systemic scleroderma	0.000297	0.000297	CcSEcCtD
Acamprosate—Insomnia—Methotrexate—systemic scleroderma	0.000295	0.000295	CcSEcCtD
Acamprosate—Paraesthesia—Methotrexate—systemic scleroderma	0.000293	0.000293	CcSEcCtD
Acamprosate—Dyspnoea—Methotrexate—systemic scleroderma	0.000291	0.000291	CcSEcCtD
Acamprosate—Somnolence—Methotrexate—systemic scleroderma	0.00029	0.00029	CcSEcCtD
Acamprosate—Hypersensitivity—Prednisone—systemic scleroderma	0.000288	0.000288	CcSEcCtD
Acamprosate—Dyspepsia—Methotrexate—systemic scleroderma	0.000287	0.000287	CcSEcCtD
Acamprosate—Decreased appetite—Methotrexate—systemic scleroderma	0.000284	0.000284	CcSEcCtD
Acamprosate—Gastrointestinal disorder—Methotrexate—systemic scleroderma	0.000282	0.000282	CcSEcCtD
Acamprosate—Asthenia—Prednisone—systemic scleroderma	0.00028	0.00028	CcSEcCtD
Acamprosate—Pain—Methotrexate—systemic scleroderma	0.000279	0.000279	CcSEcCtD
Acamprosate—Pruritus—Prednisone—systemic scleroderma	0.000276	0.000276	CcSEcCtD
Acamprosate—Feeling abnormal—Methotrexate—systemic scleroderma	0.000269	0.000269	CcSEcCtD
Acamprosate—Diarrhoea—Prednisone—systemic scleroderma	0.000267	0.000267	CcSEcCtD
Acamprosate—Gastrointestinal pain—Methotrexate—systemic scleroderma	0.000267	0.000267	CcSEcCtD
Acamprosate—Urticaria—Methotrexate—systemic scleroderma	0.000259	0.000259	CcSEcCtD
Acamprosate—Dizziness—Prednisone—systemic scleroderma	0.000258	0.000258	CcSEcCtD
Acamprosate—Body temperature increased—Methotrexate—systemic scleroderma	0.000258	0.000258	CcSEcCtD
Acamprosate—Abdominal pain—Methotrexate—systemic scleroderma	0.000258	0.000258	CcSEcCtD
Acamprosate—Vomiting—Prednisone—systemic scleroderma	0.000248	0.000248	CcSEcCtD
Acamprosate—Rash—Prednisone—systemic scleroderma	0.000246	0.000246	CcSEcCtD
Acamprosate—Dermatitis—Prednisone—systemic scleroderma	0.000246	0.000246	CcSEcCtD
Acamprosate—Headache—Prednisone—systemic scleroderma	0.000244	0.000244	CcSEcCtD
Acamprosate—Hypersensitivity—Methotrexate—systemic scleroderma	0.00024	0.00024	CcSEcCtD
Acamprosate—Asthenia—Methotrexate—systemic scleroderma	0.000234	0.000234	CcSEcCtD
Acamprosate—Nausea—Prednisone—systemic scleroderma	0.000232	0.000232	CcSEcCtD
Acamprosate—Pruritus—Methotrexate—systemic scleroderma	0.000231	0.000231	CcSEcCtD
Acamprosate—Diarrhoea—Methotrexate—systemic scleroderma	0.000223	0.000223	CcSEcCtD
Acamprosate—Dizziness—Methotrexate—systemic scleroderma	0.000216	0.000216	CcSEcCtD
Acamprosate—Vomiting—Methotrexate—systemic scleroderma	0.000207	0.000207	CcSEcCtD
Acamprosate—Rash—Methotrexate—systemic scleroderma	0.000206	0.000206	CcSEcCtD
Acamprosate—Dermatitis—Methotrexate—systemic scleroderma	0.000205	0.000205	CcSEcCtD
Acamprosate—Headache—Methotrexate—systemic scleroderma	0.000204	0.000204	CcSEcCtD
Acamprosate—Nausea—Methotrexate—systemic scleroderma	0.000194	0.000194	CcSEcCtD
